[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100466941":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":11,"centralContacts":23,"locations":33,"responsibleParty":51,"collaborators":11,"id":55,"slug":11,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":56,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":11,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":11,"overallStatus":36,"whyStopped":11,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"RenJi Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"CTC positive","ACTIVE_COMPARATOR",null,[13],"Device: GILUPI CellCollector®",{"label":15,"type":6,"description":11,"interventionNames":16},"CTC negative",[13],[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":11},"DEVICE","GILUPI CellCollector®","Use of GILUPI CellCollector® to detect CTC",[15,9],[24,29],{"name":25,"role":26,"phone":27,"phoneExt":11,"email":28},"Wenji Yin","CONTACT","86(21)68385569","followroad@163.com",{"name":30,"role":26,"phone":31,"phoneExt":11,"email":32},"Qi Lu","86(21)68383364","rjllb3364@163.com",[34],{"facility":35,"status":36,"city":37,"state":38,"zip":39,"country":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Renji Hospital, School of Medicine, Shanghai Jiao Tong University","RECRUITING","Shanghai","Shanghai Municipality","200127","China",{"type":42,"coordinates":43},"Point",[44,45],121.45806,31.22222,{"lat":45,"lon":44},[48],{"name":49,"role":26,"phone":11,"phoneExt":11,"email":50},"Jinsong Lu, MD","lujjss@163.com",{"type":52,"investigatorFullName":53,"investigatorTitle":54,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Wenjin Yin","Deputy Chief of Breast Surgery Department","100466941",false,"NCT05360290","CTCs in Breast Cancer After Neoadjuvant Treatment and Surgery: a Multicenter, Prospective Clinical Trial","The Value of Circulating Tumor Cells in Patients With Breast Cancer Who Completed Surgery After Neoadjuvant Treatment: a Multicenter, Prospective Clinical Trial","CTCNeoBC-E","Inclusion Criteria:\n\n* Female, aged ≥18 and ≤70 years;\n* Histologically confirmed invasive breast cancer (cT2-4N0-2M0 or cT1N1-3M0 before neoadjuvant treatment);\n* Completed neoadjuvant treamtment and surgery (within 4 years after surgery);\n* Administered neoadjuvant chemotherapy (regardless of chemotherapy regimen);\n* ECOG 0-1\n\nExclusion Criteria:\n\n* Metastatic disease (Stage IV);\n* Female patients who are pregnancy or lactation;\n* Uncontrollable puncture site infection or systemic infection;","FEMALE","18 Years","70 Years",{"count":66,"type":67},484,"ESTIMATED","INTERVENTIONAL",[70],"NA","The GILUPI CellCollector® is the first in vivo CTC isolation product worldwide, which is CE approved. This is a prospective, multicenter study to evaluate the prognostic value of circulating tumor cells in breast cancer patients who completed surgery after neoadjuvant treatment.",[73,74],"Breast Cancer","Circulating Tumor Cell","2026-02-01",{"date":77,"type":78},"2026-02-03","ACTUAL",{"date":80,"type":78},"2022-09-14",{"date":82,"type":67},"2029-06",{"name":5,"class":6},1]